Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct. Am J Physiol Renal Physiol 306: F410 -F421, 2014. First published November 20, 2013 doi:10.1152/ajprenal.00497.2013 is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. While known to inhibit adenylyl cyclase-mediated accumulation of intracellular cyclic AMP and potentially recruit ␤-arrestin in kidney cell lines, very little is known regarding the signaling pathways that are affected by this drug. To this end, we carried out a global quantitative phosphoproteomic analysis of native rat inner medullary collecting duct cells pretreated with satavaptan or vehicle control followed by the V2 receptor agonist desmopressin (dDAVP) for 0.5, 2, 5, or 15 min. A total of 2,449 unique phosphopeptides from 1,160 proteins were identified. Phosphopeptides significantly changed by satavaptan included many of the same kinases [protein kinase A, phosphoinositide 3-kinase, mitogenactivated protein kinase kinase kinase 7 (TAK1), and calcium/calmodulin-dependent kinase kinase 2] and channels (aquaporin-2 and urea transporter UT-A1) regulated by vasopressin. Time course clustering and kinase motif analysis suggest that satavaptan blocks dDAVP-mediated activation of basophilic kinases, while also blocking dDAVP-mediated inhibition of proline-directed kinases. Satavaptan affects a variety of dDAVP-mediated processes including regulation of cell-cell junctions, actin cytoskeleton dynamics, and signaling through Rho GTPases. These results demonstrate that, overall, satavaptan acts as a selective V2 receptor antagonist and affects many of the same signaling pathways regulated by vasopressin. This study represents the first "systems-wide" analysis of a "vaptan"-class drug and provides a wealth of new data regarding the effects of satavaptan on vasopressin-mediated phosphorylation events.
inner medullary collecting duct; iTRAQ; mass spectrometry; phosphoproteomics; vasopressin ARGININE VASOPRESSIN (AVP) is a nine-amino acid peptide hormone responsible for regulated transport of water and solutes in the renal collecting duct. AVP increases collecting duct water and urea permeability through binding to V2 receptors located on the basolateral membrane of collecting duct principal cells, which triggers stimulatory G protein (Gs)-mediated activation of adenylyl cyclase, elevation of intracellular cyclic AMP, kinase activation, and regulated phosphorylation of water channel aquaporin-2 (AQP2) (22) and urea transporter UT-A1 (3) . AVP signaling plays an important role in a number of clinical disorders including syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH), congestive heart failure, hepatic cirrhosis, and nephrogenic diabetes insipidus (NDI) (reviewed in Ref. 11) .
The "vaptans" are a class of drugs that act by inhibiting the action of AVP on its receptors (V1a, V1b, and V2). Vaptans that bind to V2 receptors in the kidney have been used clinically to treat chronic hyponatremia (19, 38) and have been shown to slow the progression of autosomal dominant polycystic kidney disease (46) . Satavaptan (SR121463) was first described as a highly potent and selective V2 receptor antagonist which inhibited AVP-stimulated adenylyl cyclase activity and produced a marked aquaretic response in rats (40) . More recently, SR121463 has been demonstrated to act as an inverse agonist of Gs ␣ signaling (e.g., it inhibits adenylyl cyclase activity even in the absence of ligand stimulation) as well as a partial agonist toward the ␤-arrestin pathway (e.g., it can recruit ␤-arrestin and stimulate the ERK MAP kinase pathway) (2, 18, 31) . SR121463 has been successfully used to treat hyponatremia associated with a variety of disorders including SIADH (42) , cirrhosis (12) , and congestive heart failure (1). It has also been shown to rescue cell surface expression of misfolded mutant isoforms of the human V2 receptor found in X-linked nephrogenic diabetes insipidus (4, 18, 26, 32) . Among similar V2 receptor antagonists, only conivaptan and tolvaptan have been approved by the US FDA (9) . Despite prevalent use, the effects of these drugs on cellular signaling pathways have not been analyzed on a global scale.
Identification and quantification of in vivo phosphorylation sites by mass spectrometry has become the method of choice for global, unbiased investigation of cellular signaling pathways (13, 15) . Multiplexed labeling methods based on isobaric tagging reagents [e.g., isobaric tags for relative and absolute quantitation (iTRAQ; 34) and tandem mass tags (TMT; 7) ] have allowed quantitative analysis of phosphorylation events across multiple time points following a physiological stimulus (16, 23, 48) . In this study, we utilize an iTRAQ-based quantitative phosphoproteomic strategy to measure phosphorylation events altered by the V2 receptor antagonist SR121463 in the presence of the V2 receptor agonist [deamino-Cys 1 ,D-Arg 8 ]vasopressin (dDAVP). We also compare these data to a prior phosphoproteomic screen of dDAVP-regulated phosphorylation events (16) to determine the extent to which SR121463-mediated and dDAVP-mediated phosphorylation events overlap. The data generated by this study expand knowledge of the cell signaling pathways regulated by AVP, while also supporting prior evidence that SR121463 acts as a specific V2 receptor antagonist.
METHODS
Experimental animals. Pathogen-free male Sprague-Dawley rats (Taconic Farms, Germantown, NY) weighing 150 -200 g were used in these studies. All experiments were conducted in accord with animal protocol H-0110R1 approved by the Animal Care and Use Committee of the National Heart, Lung, and Blood Institute.
Sample preparation for phosphoproteomic analysis. Phosphoproteomic profiling of native rat inner medullary collecting duct (IMCD) was performed according to the workflow presented in Fig. 1 . Sample preparation procedures followed those used in our previous phosphoproteomic time course study of the response of the collecting duct to dDAVP (16) . IMCD suspensions were prepared from rat kidney inner medullas (150 -250 g of protein per inner medulla) using the method of Stokes et al. (43) with modifications (29) . After isolation, IMCD suspensions were incubated in the presence or absence of 10 nM of the V2 receptor antagonist SR121463 at 37°C for 10 min followed by incubation for 0.5, 2, 5, and 15 min with 1 nM dDAVP, a V2 receptor-specific analog of vasopressin. Concentrations of antagonist and agonist were selected based on the lowest concentrations necessary to elicit significant changes in AQP2 phosphorylation (see Fig.  4 ). IMCD tubules were spun at Ͼ10,000 g for 10 s and then lysed in 150 l of lysis buffer containing 8 M urea/50 mM Tris-HCl/75 mM NaCl with 1X HALT protease and phosphatase inhibitor (Pierce, Rockford, IL). Protein samples (500 g each) were sonicated, cleared of debris, reduced, alkylated, and digested with trypsin as previously described (16) . After acidification with 0.5% formic acid, peptide samples were desalted on a 1cc Oasis HLB cartridge (Waters, Milford, MA) prior to iTRAQ labeling.
iTRAQ labeling. iTRAQ labeling was performed according to the manufacturer's protocol (Applied Biosystems, Foster City, CA). Briefly, peptide samples were resuspended in 150 l of iTRAQ dissolution buffer (0.5 M triethylammonium bicarbonate, pH 8.5). Each peptide sample was labeled with 5 units of iTRAQ 8-plex reagent for 2 h at room temperature according to the experimental workflow shown in Fig. 1 . The reaction was quenched by adding 0.5% formic acid. All eight iTRAQ-labeled samples were combined in equal quantities into a single tube, then desalted (HLB cartridges; Waters) and dried in vacuo.
Fractionation and phosphopeptide enrichment. iTRAQ-labeled samples were fractionated by strong cation exchange (SCX) chromatography followed by enrichment of phosphopeptides using Fe-NTA immobilized metal affinity chromatography (IMAC) columns (Pierce, Rockford, IL) as previously described (5) .
LC-MS/MS analysis and database searching. Samples were analyzed on an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, San Jose, CA) using previously described methods (16) . Each of two 8-plex iTRAQ biological replicates were divided equally and then run on the mass spectrometer producing a total of four technical replicates. Spectra were searched using Proteome Discoverer software (ver. 1.3.0.339, Thermo Scientific) running the SEQUEST algorithm on a concatenated database containing both the forward and reversed complement of the Rat Refseq Database (National Center for Biotechnology Information, March 12, 2012) which included a list of common contaminating proteins from other species. Search parameters were the same as previously described (16) , and data sets were filtered to include Ͻ1% false positive hits [estimated based on target-decoy analysis (10) ]. Phosphorylation site assignment was performed using the dynamic programming algorithm PhosSA (35) with deltaCn set to 0.7 (70% sensitivity) and seven peptides as the redundancy threshold. Phosphopeptides matching to multiple protein isoforms were identified using ProMatch software (45) .
iTRAQ quantification. Quantification of iTRAQ reporter ion intensities for each phosphopeptide was performed using in-house software. A precursor ion isolation purity cutoff was set at 75%. For an individual peptide, the reporter ion intensities of all corresponding MS2 scan events and charge states from all SCX fractions were summed together. Abundance ratios [(dDAVP ϩ SR121463)/dDAVP] for all four time points were calculated and each was normalized using a correction factor which was based on the ratio of the summed reporter ion intensities for each individual reporter ion channel. The log 2 of the normalized ratio was used as the basis for calculation of the mean for each peptide across all four technical replicates. Unpaired t-tests determined whether changes in phosphopeptide abundance were significant (P Ͻ 0.05). Background experimental variability was assessed for all phosphopeptides by obtaining abundance ratios across four separate vehicle-treated samples [mean log2(vehicle/vehicle) ϭ 0.007 Ϯ 0.44 (SD)]. Approximately 95% of log2 ratios were between Ϫ0.6 and 0.6.
Cluster analysis. Cluster analysis of phosphopeptides with similar temporal profiles was performed using a Temporal Pattern Mining (TPM) algorithm (http://helixweb.nih.gov/TPM/) (36) . Only phosphopeptides present in at least two technical replicates were clustered. In addition, all eight iTRAQ reporter ions needed to be present in each spectrum to obtain quantifiable iTRAQ ratios at each of the four time points.
Kinase phosphorylation motif generation. The phosphorylated residue(s) of each phosphopeptide were centered and extended out six amino acids in either direction from this position using PTM Centralizer (http://helixweb.nih.gov/ESBL/PtmCentralizer/). This list of centralized phosphopeptides was then submitted for phosphorylation motif analysis using the PhosphoLogo algorithm (http://helixweb.nih. gov/PhosphoLogo/) (8) .
Bioinformatics. Automated Bioinformatics Extractor, ABE (http:// helixweb.nih.gov/ESBL/ABE/), was used to extract gene names, protein names, and accession numbers for all data. The DAVID bioinformatic tool (Database for Annotation, Visualization and Integrated Discovery, NIAID, http://david.abcc.ncifcrf.gov/) (17) was used to extract the list of significantly enriched Gene Ontology (GO) Biolog- Inner medullary collecting duct samples from rat kidneys were incubated with or without 10 nM SR121463 (satavaptan) followed by incubation with 1 nM dDAVP for the indicated times. Samples were then processed for quantitative phosphoproteomics using the indicated workflow. IMCD, inner medullary collecting duct; SCX, strong cation exchange; IMAC, immobilized metal affinity chromatography.
ical Process terms associated with phosphopeptides altered by SR121463. DAVID calculates fold enrichment of GO terms by taking the relative abundance of each GO term altered by SR121463 and dividing it by the relative abundance of each GO term in the background data set (i.e., dDAVP vs. vehicle-treated IMCD). P values are then calculated to determine whether the fold enrichment is significant based on the relative abundance of each GO term in the two data sets (P Ͻ 0.05 is considered significant).
Immunoblotting. IMCD protein samples were diluted in Laemmli buffer (10 mM Tris, pH 6.8/1.5% SDS/6% glycerol/0.05% bromophenol blue/40 mM DTT) and subjected to SDS-PAGE. Immunoblot analysis using nitrocellulose membranes was performed as described previously (30) . Both blocking buffer and IR dye-coupled secondary antibodies were obtained from LI-COR (Lincoln, NE). Fluorescence signals from discrete bands were read out using the LI-COR Odyssey system. An antibody recognizing total Aqp2 (K5007) (14) was used at a dilution of 1:5,000, while antibodies recognizing Aqp2 phosphorylated at either Ser-256, Ser-264, or Ser-269 (PhosphoSolutions, Aurora, CO) were used at a dilution of 1:1,000. Antibodies to total ␤-catenin (Ctnnb1) (no. 9587) and phospho-␤-catenin (pS552-Ctnnb1) (no. 9566) were purchased from Cell Signaling Technology (Beverly, MA) and used at the manufacturer's recommended dilutions.
RESULTS
Phosphoproteomic profiling and quantification. Phosphoproteomic profiling of native rat inner medullary collecting duct (IMCD) was performed to assess the global ("systemswide") effects of the V2 receptor antagonist satavaptan (SR121463) in the presence of the V2 receptor agonist desmopressin (dDAVP). As indicated in the experimental workflow shown in Fig. 1 , IMCD samples were preincubated for 10 min with or without 10 nM SR121463 followed by incubation with 1 nM dDAVP for 0.5, 2, 5, and 15 min. Samples were then digested with trypsin, labeled with eight distinct isobaric tagging reagents (8-plex iTRAQ), mixed together, and analyzed by quantitative LC-MS/MS-based phosphoproteomics.
A total of 2,449 unique phosphopeptides with 2,551 phosphorylation sites were identified from 1,160 proteins among four technical replicate LC-MS/MS runs ( Fig. 2A and Supplemental Table S1 , available with the online version of this article). The vast majority of phosphorylation sites (86%) were phosphorylated on serine residues. Figure 2B shows a histogram of all quantified phosphopeptide abundance ratios at each time point, showing that the majority of phosphopeptides did not change in the presence of SR121463 {mean log 2 [(SR121463 ϩ dDAVP)/dDAVP] ϭ 0.005 Ϯ 0.369 SD}. The dashed lines in Fig. 2B represent the 95% confidence interval defined on the basis of preliminary experiments where all samples were vehicle treated. Based on this confidence threshold, as well as a second criterion (P value Ͻ 0.05 based on unpaired t-test), 90 phosphopeptides decreased in abundance while 43 phosphopeptides increased in the presence of both SR121463 and dDAVP vs. dDAVP alone (Supplemental Table S2 , available with the online version of this article). These included many serine/threonine kinases (Mast3, Map3k3, Pak4, Prpf4b, and Wnk4), PDZ domain-containing proteins (Inadl, Magi3, Mast3, Shroom2, and Shroom3), Rho GTPase-activator proteins (Arhgap35/Grlf1, Arhgap6, Srgap2, and Srgap3), and RNA Recognition Motif domain-containing proteins (Acin1, Hnrpd, Raver1, Srsf2, Srsf11, and Slirp). Over twice as many phosphopeptides decreased than increased in the presence of SR121463, and the histogram reflects this trend by being skewed to the left (skewness ϭ Ϫ0.8785).
Correlation among "SR121463 ϩ dDAVP" and "dDAVP alone" data sets. Table 1 , A and B, includes phosphopeptides that changed significantly with SR121463 that were also identified as being significantly regulated in our prior phosphoproteomic time course study of the effects of dDAVP in IMCD (16) . Phosphopeptides in Table 1 have been plotted as a scatterplot to show the degree of correlation among both data sets (Fig. 3) . Overall the data show a high degree of correlation (R 2 ϭ 0.81) with phosphopeptides from Table 1A showing strong negative correlation, while phosphopeptides from Table  1B show strong positive correlation. Table 1A includes those phosphopeptides that were reciprocally altered by SR121463 (i.e., those phosphopeptides that increased in our prior study with dDAVP alone, but decreased with SR121463 in the presence of dDAVP in the current study, or vice versa). This list includes well-known channel proteins, namely aquaporin-2 (Aqp2) and urea transporter UT-A1 (Slc14a2), as well as signaling proteins such as ␤-catenin (Ctnnb1) and Bok (Bok) that undergo changes in phosphorylation in response to vasopressin (16, 25) . Changes in AQP2 and ␤-catenin phosphorylation with SR121463 were confirmed by immunoblotting (Fig. 4) . Phosphorylation of AQP2 at residues S256, 264, and 269 significantly increased with dDAVP, while phosphorylation at these sites was significantly reduced in the presence of SR121463 (Fig. 4, B, D , and E, respectively). In contrast, phosphorylation of AQP2 at residue S261 significantly decreased with dDAVP, but increased to vehicle control levels in the presence of SR121463 (Fig. 4C) . Phosphorylation of ␤-catenin at S552 significantly increased with dDAVP, and this increase was blocked by SR121463 (Fig. 4F) . Table 1A also includes three protein kinases (Camkk2, Map3k7, and Prkar1a) that were reciprocally altered by SR121463 compared with dDAVP alone. The S83 phosphorylation site in the cAMP-dependent protein kinase type I-alpha regulatory subunit (Prkar1a) is of particular interest given the importance of the cAMP-PKA pathway in vasopressin signaling. Taken together, these results demonstrate that, in the presence of dDAVP, SR121463 modulates many of the same important target proteins as dDAVP, and reinforces the claim that SR121463 is a potent V2-receptor-selective antagonist (39, 40) . Compared with Table 1A, Table 1B contains far fewer phosphopeptides that were not reciprocally altered by SR121463 compared with dDAVP alone. Prior studies have shown that SR121463 can act as a "biased agonist" through its inverse agonist activity on Gs signaling and potential to recruit ␤-arrestin (2, 31). Neither isoforms of ␤-arrestin nor isoforms of G protein-coupled receptor kinases (GRKs) were identified in this study, making it difficult to determine whether SR121463 is affecting ␤-arrestin signaling in this study. However, the phosphorylation events listed in Table 1B may indeed indicate potential "biased agonist" effects of the drug. These proteins are associated with pathways known to be regulated by vasopressin including prostanoid biosynthesis (Pla2g4a) (49) , regulation of the actin cytoskeleton (Hspb1, Ahnak) (28, 41) , Wnt/␤-catenin signaling (Lrrfip2) (16) , and apoptosis (Pdcd4) (25) . Biological processes associated with proteins altered by SR121463 in the presence of dDAVP. Far more phosphopeptides were altered by SR121463 than the ones listed in Table 1 , A and B. Therefore, to get a broader view of the effects of SR121463 in the presence of dDAVP in collecting duct, Gene Ontology (GO) Biological Process terms were extracted for all phosphopeptides that changed in abundance (P Ͻ 0.05) with SR121463. The fold enrichment for each GO term was then calculated based on the relative abundance of each GO term in a background data set of phosphopeptides from dDAVP vs. vehicle-treated IMCD (DAVID analysis; see METHODS). Significantly enriched (P Ͻ 0.05) GO terms based on this analysis are shown in Fig. 5 . All of these GO term categories were present in our prior phosphoproteomic study of the collecting duct response to dDAVP (16), indicating that both agonist (dDAVP) and antagonist (SR121463) are likely affecting similar cellular processes. Proteins that were regulated in both studies are listed by gene name in the figure. Full results are available in Supplemental Table S3 , available with the online version of this article. Similar to dDAVP, many of the processes altered by SR121463 are associated with regulation of the cytoskeleton ("negative regulation of cytoskeleton organization," "microtubule cytoskeleton organization," "microtubule-based process," and "cytoskeleton organization"), reinforcing the growing evidence that the actin and microtubulebased cytoskeleton plays a crucial role in vasopressin signaling (6, 21, 44, 47) . Analysis by Ingenuity Pathway Analysis software (www.ingenuity.com) revealed common functional annotations involving regulation of cytoskeletal dynamics along with common gene lists known to be involved in a number of other processes, including "vasopressin signaling" (including Aqp2 and Slc14a2), "mechanisms of gene regulation by peroxisome proliferators via PPAR␣" (including Map3k7, Sos1, and Stat5a) and "renal necrosis/cell death" (including Bok, ATP1a1, Hspb1, Pla2g4a, and Tjp2). These functional annotations were not present in an analysis of a control data set (i.e., those phosphopeptides that are neither regulated by dDAVP nor altered by SR121463).
Kinase phosphorylation motif analysis of the collecting duct response to SR121463. To classify the kinases that may be involved in regulating the collecting duct response to SR121463, we carried out motif analysis of the residues surrounding each site of phosphorylation for significantly regulated (P Ͻ 0.05) phosphopeptides during each time point (Fig. 6) . Motifs that increased with SR121463 (left column) contained a dominant proline (P) in the ϩ1 position and a smaller contribution from arginine (R) at the Ϫ3 position. Motifs that decreased with SR121463 (right column) displayed a noticeable trend. As the time of dDAVP incubation increased, the relative contribution of each residue changed, with proline in the ϩ1 position becoming less dominant and the arginine in the Ϫ3 position becoming more dominant. These results indicate that SR121463 may decrease the activity of "basophilic" kinases (i.e., those kinases that are dependent upon either arginine or lysine at position Ϫ3) while also increasing the activity of "proline-directed" kinases (i.e., those kinases that are dependent upon proline at position ϩ1) that are affected by dDAVP. Prior studies have indeed shown that dDAVP upregulates basophilic kinases and downregulates proline-directed kinases based on both motif analysis (16, 33) and biochemical data (27, 30) . These results were confirmed when phosphopeptides were initially clustered based on their temporal patterns across all four time points using a temporal pattern mining (TPM) algorithm (see METHODS) prior to kinase phosphorylation motif generation. TPM analysis generated 30 distinct clusters of phosphopeptides and motifs were generated for all clusters (Supplemental Table S4 , available with the online version of this article). An example of a cluster of phosphopeptides that decreased at all time points along with its corresponding kinase motif is shown in Fig. 7A . The motif for this cluster includes a predominant arginine at the Ϫ3 position, indicating that SR121463 blocks the dDAVP-mediated activation of basophilic kinases including the AGC (e.g., PKA) and/or Ca ϩ2 -calmodulin-dependent kinase groups (24) . A cluster of phosphopeptides that increased at all time points displays a motif with a proline at the ϩ1 position consistent with proline-directed kinases of the CMGC group (Fig. 7B) , indicating that SR121463 blocks the dDAVP-mediated inhibition of members of the mitogen activated protein (MAP) kinase and/or cyclin-dependent kinase groups. These results reveal that the overall effects of SR121463 on kinase pathways is the mirror image of the effects of dDAVP, consistent with SR121463 acting as a V2 receptor-specific antagonist.
Pathways analysis of the collecting duct response to SR121463. The list of gene names associated with phosphopeptides significantly altered by SR121463 was compared with the list of gene names associated with phosphopeptides significantly regulated by dDAVP in our prior study (16) to determine the included in Table 1A included in Table 1B Fig degree of overlap between affected signaling pathways (full results in Supplemental Table S5 , available with the online version of this article). The most significantly enriched canonical signaling pathways from both data sets based on hierarchical clustering of Ϫlog(P values) are shown in Fig. 8A . The top four pathways all involve regulation of cell-cell junctions, indicating that both SR121463 and dDAVP may regulate the assembly and/or stability of these structures. The top signaling Ϫ7 , and 10 Ϫ8 M) for 10 min followed by addition of 1 nM dDAVP or vehicle for 20 min. A: immunoblots probed with antibodies recognizing AQP2 phosphorylated at Ser-256 (pS256-AQP2), Ser-261 (pS261-AQP2), and Ser-269 (pS269-AQP2); total AQP2, ␤-catenin phosphorylated at Ser-552 (pS552-Ctnnb1), and total Ctnnb1. B-F: band densities from replicate immunoblots (n ϭ 3) were normalized to the corresponding total protein signal and then plotted as the relative band density for each condition. Error bars indicate SE. *P value Ͻ 0.05 vs. dDAVP alone.
pathway, "cell-cell junction signaling" (Fig. 8B) , reveals a high degree of overlap among the two data sets (pink nodes), including components of both tight junctions (ZO1, ZO2, afadin, cingulin, and spectrin) and adherens junctions (CTNN␣ and CTNN␤). However, we also found a number of proteins that were unique to either study (blue and yellow nodes), demonstrating the importance of integrating multiple data sets to increase coverage. Another canonical pathway, "actin cytoskeleton signaling," reveals that both SR121463 and dDAVP may regulate various types of actin cytoskeletal dynamics (Fig.  8C) . Prior studies showing that vasopressin can regulate cytoskeletal dynamics (41) and that depolymerization of the cortical actin network promotes AQP2 trafficking (21, 28) support this finding. Other proteins that were shared among the top canonical signaling pathways (Supplemental Table S5 ) included various components of MAP kinase signaling (MAP3K7, MAPK14/ p38-␣, RAF1, and SOS1) as well as multiple Rho guanine nucleotide exchange factor (GEF) isoforms (ARHGEF2, ARHGEF5, and ARHGEF11). Both MAP kinase pathways (27, 30) and signaling through Rho GTPases (21, 44) have been implicated in vasopressin-mediated signaling.
DISCUSSION
We have applied a temporal quantitative phosphoproteomic strategy to study the global effects of the V2 receptor antagonist SR121463 on vasopressin-mediated phosphorylation events. This study represents the first systems-wide analysis of a "vaptan" class compound and reinforces prior evidence that SR121463 acts as a specific V2 receptor antagonist (40) . This study also adds to the growing body of evidence that both posttranscriptional and posttranslational regulatory mechanisms play important roles in regulating the cellular signaling pathways downstream of the V2 receptor (20, 37) . Overall, SR121463 affects many of the same dDAVP-regulated phosphorylation events. Most of these events were reciprocal in nature and highlight the same kinase pathways (e.g., PKA, MAP3K7, PI3K/AKT, and CAMKK2) and downstream effectors (e.g., AQP2, UT-A1, CTNNB1, and BOK) regulated by dDAVP. In a previous phosphoproteomic study (16) , we found that many more phosphopeptides increased than decreased with dDAVP alone, consistent with the hypothesis that dDAVP produces a net increase in cellular phosphorylation. In the current study, over twice as many phosphopeptides decreased than increased with SR121463 in the presence of dDAVP, revealing that SR121463 is likely acting as a global inhibitor of dDAVP-regulated phosphorylation.
Based on analysis of kinase target sequences, both SR121463 and dDAVP appear to regulate the same groups of protein kinases. There were clear reciprocal changes in basophilic and proline-directed kinase motifs in samples treated with SR121463 in the presence of dDAVP vs. samples treated with dDAVP alone. Results of the motif analyses suggest that SR121463 blocks dDAVP-mediated activation of basophilic kinases, while also blocking dDAVP-mediated inhibition of proline-directed kinases. The effect of SR121463 on basophilic motifs likely stems, at least partially, from its ability to inhibit production of intracellular cAMP by acting as an antagonist of Gs-mediated signaling (2, 31) . Other than basophilic and proline-directed motifs, no other dominant kinase motif was identified with SR121463, suggesting that SR121463 is not spuriously affecting other kinase pathways.
The current study provides new evidence for involvement of small GTP-binding proteins of the Rho family in V2 receptormediated signaling. Four distinct isoforms of Rho guanine nucleotide exchange factors (ARHGEF2, ARHGEF5, ARH-GEF7, and ARHGEF11) were altered by SR121463, three of which (isoforms 2, 5, and 11) are also regulated by dDAVP (16) . These proteins activate monomeric GTPases of the Rho family (e.g., Cdc42, Rac1, and RhoA) by stimulating the dissociation of GDP to allow binding of GTP. A number of Rho GTPase-activator protein (GAP) isoforms were also altered by SR121463. These proteins inactivate small GTPases by stimulating their GTPase activity. Previous studies have implicated Rho family GTPases in inhibiting AVP-mediated translocation of AQP2 water channels to the apical plasma membrane of kidney collecting duct cells via stabilization of the F-actin cytoskeleton (21, 44) . Our current results suggest that modulation of Rho GTPase activity by RhoGEF and RhoGAP family members may play an important role in AVP signaling.
AVP, which is the natural ligand of the V2 receptor, is a full agonist toward both Gs and ␤-arrestin signaling pathways (31). SR121463, while clearly an effective V2 receptor antagonist, also displays properties of a "biased agonist" in other systems: it can act alone as an inverse agonist to Gs signaling and as a partial agonist of ␤-arrestin (2, 31) . Due to the limited number of conditions allowed by the iTRAQ quantification technique, we did not incorporate an examination of the effects of SR121463 alone (in the absence of dDAVP) to assess the potential for any biased agonist behavior in native IMCD cells. Thus we cannot exclude the possibility that some of the phosphorylation changes described in this study may also occur with SR121463 alone. Phosphoproteins that did not demonstrate reciprocal regulation (Table 1B) could reveal the drug's partial agonist activities toward components of the ␤-arrestin and ERK MAP kinase signaling pathways. Regardless, the current study provides strong evidence that SR121463 is a specific V2 receptor antagonist toward Gs-mediated signaling pathways and globally affects many of the same processes that are regulated by AVP. Systems-wide analysis of other members of the "vaptan" class of drugs should allow a deeper understanding of their efficacy and safety for future clinical use. Fig. 8 . Top canonical signaling pathways regulated by dDAVP that are also affected by treatment with SR121463. Pathways analysis software (www.ingenuity.com) was used to compare two distinct phosphopeptide data sets: dDAVP alone (dDAVP) and dDAVP in the presence of SR121463 (SR). A heat map shows the most significantly enriched canonical signaling pathways for both data sets based on hierarchical clustering of Ϫlog(P values) (A). Two of the top canonical pathways represented in both data sets were "cell-cell junction signaling" (B) and "actin cytoskeleton signaling" (C). Proteins that were previously found to be regulated by dDAVP alone are in yellow, while proteins that were altered by SR121463 in the presence of dDAVP are in blue. Proteins that were found in both data sets are in pink. Only phosphopeptides that were significantly regulated (P Ͻ 0.05) were included in this analysis. 
